1. Cell Cycle/DNA Damage
  2. DNA/RNA Synthesis
    CRISPR/Cas9

SCR7 

Cat. No.: HY-12742 Purity: 99.75%
Handling Instructions

SCR7 is a DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ). SCR7 increases CRISPR/Cas9-mediated editing frequency.

For research use only. We do not sell to patients.
SCR7 Chemical Structure

SCR7 Chemical Structure

CAS No. : 1533426-72-0

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 92 In-stock
5 mg USD 84 In-stock
10 mg USD 144 In-stock
50 mg USD 420 In-stock
100 mg   Get quote  
200 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

SCR7 is a DNA Ligase IV inhibitor, blocks nonhomologous end-joining (NHEJ). SCR7 increases CRISPR/Cas9-mediated editing frequency.

IC50 & Target

DNA Ligase IV[1]
CRISPR/Cas9[2]

In Vitro

SCR7 inhibits joining of double-strand breaks (DSBs) in cell-free repair system. SCR7 blocks Ligase IV-mediated joining by interfering with its DNA binding but not that of T4 DNA Ligase or Ligase I. SCR7 inhibits NHEJ in a Ligase IV-dependent manner within cells, and activates the intrinsic apoptotic pathway. Results show a dose-dependent decrease in cell proliferation of MCF7, A549, and HeLa with an IC50 of 40, 34, and 44 μM, respectively, which is further confirmed by DIC imaging in MCF7. T47D, A2780, and HT1080 are also sensitive to SCR7, with an IC50 of 8.5, 120, and 10 μM, respectively[1].

In Vivo

SCR7 treatment (10 mg/kg, six doses) significantly reduces breast adenocarcinoma-induced tumor. Untreated tumor animals survived only for 52 days, whereas treated animals exhibit ~4-fold increase in lifespan[1].

References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 2.9905 mL 14.9526 mL 29.9052 mL
5 mM 0.5981 mL 2.9905 mL 5.9810 mL
10 mM 0.2991 mL 1.4953 mL 2.9905 mL
Please refer to the solubility information to select the appropriate solvent.
Cell Assay
[3]

SCR7 is dissolved in DMSO and stored, and then diluted with appropriate medium before use[3].

Wild-type, AAVS1TLR HEK293 and mouse NIH3T3 cells are maintained in DMEM supplied with 15% FBS, cells are passaged three times per week. The mouse Burkitt lymphoma cell line, generated from a Burkitt-like mouse lymphoma is maintained in DMEM supplied with 15% FBS, 2 mM HEPES, 2 mM sodium pyruvate, 2 mM L-glutamine, and 1× NAA, beta-mercaptoethanol and passaged four times per week. For puromycin selection, mCherry+ cells are sorted, seeded at 103 cells/well and selected with 3 mg/mL of Puromycin for 2 weeks. Then colonies are counted and single cells are sorted. The SCR7 inhibitor is purchased, 12 h after transfection these cells are maintained in complete medium supplied with 1 mM SCR7 inhibitor until analysis. At SCR7 concentrations of 60 mM and 10 mM, A reduction of transfection efficiency and of cell viability is observed[3]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

SCR7 is prepared in DMSO and diluted.

Mice[1]
BALB/c mice are injected with DLA cells (0.25×106) intraperitoneally for tumor development, after which two batches of animals are divided into eight subgroups. Treatment is started after 5 days of DLA injection (d 0). Group I serves as tumor control (n=10). Group II (IR, n=5) and III (IR+SCR7, n=5) receive two doses of radiation (2 Gy) on day 0 and 4. Besides radiation, Group III also receives six doses of SCR7 (20 mg/kg) on alternate days from day 0. Group IV (Etoposide, n=5) and V (Etoposide+SCR7, n=5) received three doses of Etoposide (10 mg/kg) intraperitoneally on day 0, 4, and 8. In addition to Etoposide, Group V animals also receive six doses of SCR7 (20 mg/kg) on alternate days from day 0. Group VI (3-ABA, n=5) and VII (3-ABA+SCR7, n=5) received three doses of 3-Aminobenzamide (10 mg/kg) on days 0, 4, and 8. Group VII receives six doses of SCR7. Group VIII (SCR7, n=5) receives six doses of SCR7 alone (20 mg/kg) on alternate days (0, 2, 4, 6, 8, and 10) and serves as the control. Progression of tumor is monitored and data are presented as a bar diagram. Error bars and levels of significance are indicated in respective figure legends. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References
Molecular Weight

334.39

Formula

C₁₈H₁₄N₄OS

CAS No.

1533426-72-0

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 45 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
SCR7
Cat. No.:
HY-12742
Quantity: